Company intelligence / Profile preview

AMMTeK

Ownership: Private
Development stage: Other

Overview

AMMTeK developed amglidia, a proprietary liquid formulation of glibenclamide for the treatment of neonatal diabetes mellitus. The product is approved in Europe and has been commercialized there. In November 2024, Eton Pharmaceuticals acquired the U.S. rights to amglidia.

Therapeutic areas: Endocrinology
Modalities: Small molecule
Industry: Biotech

Partnerships

Eton Pharmaceuticals (U.S. commercialization partner for amglidia)

Beyond the preview

Go deeper on AMMTeK.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AMMTeK.

Explore the full profile